What to know
Tuberculosis Cases and Percentages by Completion of Therapy Among Those Eligible to Complete Within One Year: United States, 1993–2021
| Year | Total cases1,2 | Completed therapy3 | Did not complete therapy4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | ≤1 year | >1 year | Duration unknown | ||||||||
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||
| 2021 | 6,241 | 5,865 | (94.0) | 5,420 | (86.8) | 389 | (6.2) | 56 | (0.9) | 376 | (6.0) |
| 2020 | 5,745 | 5,456 | (95.0) | 5,125 | (89.2) | 314 | (5.5) | 17 | (0.3) | 289 | (5.0) |
| 2019 | 7,212 | 6,898 | (95.6) | 6,500 | (90.1) | 389 | (5.4) | 9 | (0.1) | 314 | (4.4) |
| 2018 | 7,385 | 7,077 | (95.8) | 6,605 | (89.4) | 465 | (6.3) | 7 | (0.1) | 308 | (4.2) |
| 2017 | 7,420 | 7,145 | (96.3) | 6,698 | (90.3) | 432 | (5.8) | 15 | (0.2) | 275 | (3.7) |
| 2016 | 7,612 | 7,280 | (95.6) | 6,786 | (89.1) | 477 | (6.3) | 17 | (0.2) | 332 | (4.4) |
| 2015 | 7,877 | 7,591 | (96.4) | 7,095 | (90.1) | 491 | (6.2) | 5 | (0.1) | 286 | (3.6) |
| 2014 | 7,748 | 7,486 | (96.6) | 6,975 | (90.0) | 500 | (6.5) | 11 | (0.1) | 262 | (3.4) |
| 2013 | 7,782 | 7,493 | (96.3) | 6,988 | (89.8) | 495 | (6.4) | 10 | (0.1) | 289 | (3.7) |
| 2012 | 8,090 | 7,808 | (96.5) | 7,295 | (90.2) | 495 | (6.1) | 18 | (0.2) | 282 | (3.5) |
| 2011 | 8,468 | 8,170 | (96.5) | 7,597 | (89.7) | 569 | (6.7) | 4 | (0.0) | 298 | (3.5) |
| 2010 | 9,054 | 8,700 | (96.1) | 8,110 | (89.6) | 580 | (6.4) | 10 | (0.1) | 354 | (3.9) |
| 2009 | 9,494 | 9,075 | (95.6) | 8,432 | (88.8) | 632 | (6.7) | 11 | (0.1) | 419 | (4.4) |
| 2008 | 11,008 | 10,273 | (93.3) | 9,473 | (86.1) | 797 | (7.2) | 3 | (0.0) | 735 | (6.7) |
| 2007 | 11,392 | 10,695 | (93.9) | 9,746 | (85.6) | 947 | (8.3) | 2 | (0.0) | 697 | (6.1) |
| 2006 | 11,641 | 10,846 | (93.2) | 9,868 | (84.8) | 976 | (8.4) | 2 | (0.0) | 795 | (6.8) |
| 2005 | 11,944 | 11,045 | (92.5) | 10,029 | (84.0) | 1,015 | (8.5) | 1 | (0.0) | 899 | (7.5) |
| 2004 | 12,355 | 11,436 | (92.6) | 10,414 | (84.3) | 1,015 | (8.2) | 7 | (0.1) | 919 | (7.4) |
| 2003 | 12,637 | 11,722 | (92.8) | 10,562 | (83.6) | 1,155 | (9.1) | 5 | (0.0) | 915 | (7.2) |
| 2002 | 12,707 | 11,753 | (92.5) | 10,544 | (83.0) | 1,208 | (9.5) | 1 | (0.0) | 954 | (7.5) |
| 2001 | 13,506 | 12,522 | (92.7) | 11,142 | (82.5) | 1,374 | (10.2) | 6 | (0.0) | 984 | (7.3) |
| 2000 | 13,729 | 12,702 | (92.5) | 11,280 | (82.2) | 1,419 | (10.3) | 3 | (0.0) | 1,027 | (7.5) |
| 1999 | 14,658 | 13,508 | (92.2) | 11,931 | (81.4) | 1,575 | (10.7) | 2 | (0.0) | 1,150 | (7.8) |
| 1998 | 15,227 | 14,040 | (92.2) | 12,370 | (81.2) | 1,662 | (10.9) | 8 | (0.1) | 1,187 | (7.8) |
| 1997 | 16,324 | 14,861 | (91.0) | 12,849 | (78.7) | 1,998 | (12.2) | 14 | (0.1) | 1,463 | (9.0) |
| 1996 | 17,413 | 15,712 | (90.2) | 13,370 | (76.8) | 2,328 | (13.4) | 14 | (0.1) | 1,701 | (9.8) |
| 1995 | 18,453 | 16,461 | (89.2) | 13,671 | (74.1) | 2,775 | (15.0) | 15 | (0.1) | 1,992 | (10.8) |
| 1994 | 19,455 | 16,894 | (86.8) | 13,346 | (68.6) | 3,523 | (18.1) | 25 | (0.1) | 2,561 | (13.2) |
| 1993 | 19,896 | 17,115 | (86.0) | 12,621 | (63.4) | 4,476 | (22.5) | 18 | (0.1) | 2,781 | (14.0) |
1Persons for whom less than one year of therapy was indicated.
2Excludes patients who died within one year of initiating therapy; patients with an initial isolate resistant to rifampin; patients with bone and joint disease, meningeal disease, or disease of the central nervous system; or patients <15 years of age with miliary disease, positive blood culture, or a positive nucleic acid amplification test on a blood specimen. Beginning in 2011, patients who moved out of the country within one year of initiating therapy were also excluded.
3Percentages calculated based on the number of total cases among persons for whom less than one year of therapy was indicated.
4Includes persons for whom reason for stopping therapy was unknown.
Note
Data for all years are updated through July 17, 2024.
Zero % (0.0) denotes <0.05%.